Pemphigus miss further dents prospects for argenx’s Vyvgart

Another negative clinical readout for Vyvgart will remove at least one indication from argenx’s pipeline-in-a-product goals for the drug, while also threatening its prospects in a second, larger indication.

The miss by Vyvgart efgartigimod in the Phase III ADDRESS study to treat pemphigus vulgaris or pemphigus foliaceus resulted in the loss by argenx SE (Euronext:ARGX; NASDAQ:ARGX) of 25% of its market value on NASDAQ, cutting its market cap to $20 billion...